KR102287541B1 - 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 - Google Patents

유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 Download PDF

Info

Publication number
KR102287541B1
KR102287541B1 KR1020217010949A KR20217010949A KR102287541B1 KR 102287541 B1 KR102287541 B1 KR 102287541B1 KR 1020217010949 A KR1020217010949 A KR 1020217010949A KR 20217010949 A KR20217010949 A KR 20217010949A KR 102287541 B1 KR102287541 B1 KR 102287541B1
Authority
KR
South Korea
Prior art keywords
human
cells
mouse
csf
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217010949A
Other languages
English (en)
Korean (ko)
Other versions
KR20210044315A (ko
Inventor
리차드 에이. 플라벨
마르쿠스 만츠
안토니 롱박스
틸 스트로위그
팀 윌링거
앤드류 제이. 머피
션 스티븐스
조지 얀코풀로스
Original Assignee
예일 유니버시티
인스티튜트 포 리서치 인 바이오메드슨
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예일 유니버시티, 인스티튜트 포 리서치 인 바이오메드슨, 리제너론 파마슈티칼스 인코포레이티드 filed Critical 예일 유니버시티
Priority to KR1020217024519A priority Critical patent/KR102340059B1/ko
Publication of KR20210044315A publication Critical patent/KR20210044315A/ko
Application granted granted Critical
Publication of KR102287541B1 publication Critical patent/KR102287541B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217010949A 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 Active KR102287541B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217024519A KR102340059B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261698002P 2012-09-07 2012-09-07
US61/698,002 2012-09-07
US201361775171P 2013-03-08 2013-03-08
US61/775,171 2013-03-08
PCT/US2013/058448 WO2014039782A2 (en) 2012-09-07 2013-09-06 Genetically modified non-human animals and methods of use thereof
KR1020157008697A KR102241962B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157008697A Division KR102241962B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217024519A Division KR102340059B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법

Publications (2)

Publication Number Publication Date
KR20210044315A KR20210044315A (ko) 2021-04-22
KR102287541B1 true KR102287541B1 (ko) 2021-08-10

Family

ID=50237767

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020227041881A Active KR102594390B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020157008697A Active KR102241962B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020217040735A Active KR102473555B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020247007446A Pending KR20240045263A (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020217010949A Active KR102287541B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020237036218A Active KR102645622B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020217024519A Active KR102340059B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법

Family Applications Before (4)

Application Number Title Priority Date Filing Date
KR1020227041881A Active KR102594390B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020157008697A Active KR102241962B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020217040735A Active KR102473555B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020247007446A Pending KR20240045263A (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237036218A Active KR102645622B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
KR1020217024519A Active KR102340059B1 (ko) 2012-09-07 2013-09-06 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법

Country Status (18)

Country Link
US (6) US9820476B2 (enExample)
EP (3) EP4193834B1 (enExample)
JP (5) JP6283031B2 (enExample)
KR (7) KR102594390B1 (enExample)
CN (4) CN108782459B (enExample)
AU (3) AU2013312359B8 (enExample)
CA (1) CA2881468C (enExample)
DK (1) DK2892330T3 (enExample)
ES (2) ES3034290T3 (enExample)
FI (1) FI2892330T3 (enExample)
IL (4) IL307969B1 (enExample)
IN (1) IN2015DN02032A (enExample)
MX (2) MX364714B (enExample)
NZ (3) NZ741951A (enExample)
PT (1) PT2892330T (enExample)
RU (2) RU2768282C2 (enExample)
SG (2) SG10201701759VA (enExample)
WO (1) WO2014039782A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
EP4193834B1 (en) 2012-09-07 2025-05-14 Yale University Methods of using genetically modified mice
KR102402806B1 (ko) 2012-11-05 2022-05-30 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
LT3175706T (lt) 2013-09-23 2019-02-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną
RU2674910C2 (ru) 2013-10-15 2018-12-13 Регенерон Фармасьютикалс, Инк. Животные с гуманизированным геном il-15
US20150143559A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
CA3225091A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
RU2711744C1 (ru) 2014-05-19 2020-01-21 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные животные, отличные от человека, экспрессирующие epo человека
SMT201900178T1 (it) 2014-12-05 2019-05-10 Regeneron Pharma Animali diversi dall’uomo aventi un gruppo umanizzato del gene 47 di differenziazione
IL282649B (en) 2014-12-09 2022-07-01 Regeneron Pharma Non-human animals with a humanized gene for differentiation cluster 274
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2016168212A1 (en) 2015-04-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Humanized sirpa-il15 knockin mice and methods of use thereof
PL3376857T3 (pl) 2015-11-20 2021-09-13 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek posiadające humanizowany gen aktywacji limfocytów 3
CN108779159B (zh) 2016-02-04 2022-12-30 瑞泽恩制药公司 具有经改造的angptl8基因的非人动物
EP3422845B1 (en) 2016-02-29 2021-06-02 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
CN106119284A (zh) * 2016-06-27 2016-11-16 北京维通达生物技术有限公司 一种用于构建免疫缺陷动物模型的产品及其应用
US20190320633A1 (en) * 2016-11-30 2019-10-24 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
RU2019140867A (ru) * 2017-05-12 2021-06-15 Зе Джексон Лаборатори Nsg мыши, не имеющие mhc класса i и класса ii
WO2020018511A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
US20210355501A1 (en) * 2018-09-24 2021-11-18 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
CN111118019B (zh) * 2018-12-25 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il3基因改造非人动物的构建方法及应用
US20220354098A1 (en) * 2019-07-17 2022-11-10 Yale University Genetically Modified Non-Human Animals and Methods of Use Thereof
US20220408704A1 (en) * 2019-11-01 2022-12-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with human or chimeric thpo
US11339279B2 (en) * 2020-04-01 2022-05-24 Chevron Phillips Chemical Company Lp Dual catalyst system for producing LLDPE and MDPE copolymers with long chain branching for film applications
WO2022222958A1 (en) * 2021-04-20 2022-10-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
CN119654068A (zh) 2022-07-19 2025-03-18 瑞泽恩制药公司 转基因动物模型及其模拟人类免疫系统的用途
AU2024304358A1 (en) 2023-06-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025171307A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200982A1 (en) * 2009-10-06 2011-08-18 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US20120157667A1 (en) * 2009-06-29 2012-06-21 Qingfeng Chen Methods Of Producing Humanized Non-Human Mammals
WO2012040207A3 (en) 2010-09-20 2012-08-09 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
ATE119197T1 (de) 1987-12-23 1995-03-15 Univ Leland Stanford Junior Schimäre immunkompromittierende säugetiere und ihre verwendung.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
EP0438053B1 (en) 1990-01-15 1999-06-16 Yeda Research And Development Company Limited Durable engraftment and development of human hematopoietic lineages in normal mammals
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
CA2063408A1 (en) 1990-05-03 1991-11-04 Susan Mayo Human lymphoid tissue in an immunocompromised host
EP0484512A4 (en) 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
EP0571525A1 (en) 1991-02-11 1993-12-01 OMMAYA, Ayub K. Spinal fluid driven artificial organ
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
US5663481A (en) 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
CA2195678A1 (en) 1994-07-27 1996-02-08 Joseph A. Borkowski Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
CA2284689C (en) 1997-04-09 2009-10-06 Lung-Ji Chang Animal model for evaluation of vaccines
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
CA2382383A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
WO2001042484A1 (en) 1999-12-09 2001-06-14 Human Genome Sciences, Inc. Il-6 like polynucleotide
WO2002022786A1 (en) 2000-09-14 2002-03-21 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR101015913B1 (ko) * 2001-07-10 2011-02-23 존슨 앤드 존슨 리서치 피티와이 리미티드 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도
US20030124091A1 (en) 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
JPWO2004005496A1 (ja) 2002-07-05 2005-11-04 麒麟麦酒株式会社 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
JP2005537805A (ja) 2002-09-09 2005-12-15 カリフォルニア インスティチュート オブ テクノロジー ヒト化マウスを作成するための方法および組成物
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
DE60322426D1 (enExample) 2002-12-16 2008-09-04 Genentech Inc
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
ES2618787T5 (es) 2006-04-25 2022-10-21 Univ California Administración de factores de crecimiento para el tratamiento de trastornos del SNC
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
WO2008069659A1 (en) 2006-12-05 2008-06-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
AU2008262487B2 (en) 2007-05-23 2013-10-31 Sangamo Therapeutics, Inc. Methods and compositions for increased transgene expression
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2257250A2 (en) 2008-01-29 2010-12-08 Gilbert H. Kliman Drug delivery devices, kits and methods therefor
US20120251528A1 (en) * 2009-06-29 2012-10-04 Leskov Ilya B Non-Human Mammal Model Of Human Hematopoietic Cancer
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
RS55949B1 (sr) 2011-10-28 2017-09-29 Regeneron Pharmaeuticals Inc Humanizovani il-6 i il-6 receptor
EP4193834B1 (en) 2012-09-07 2025-05-14 Yale University Methods of using genetically modified mice
KR102402806B1 (ko) 2012-11-05 2022-05-30 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
LT3175706T (lt) 2013-09-23 2019-02-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną
RU2674910C2 (ru) 2013-10-15 2018-12-13 Регенерон Фармасьютикалс, Инк. Животные с гуманизированным геном il-15
RU2711744C1 (ru) 2014-05-19 2020-01-21 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные животные, отличные от человека, экспрессирующие epo человека
WO2016168212A1 (en) 2015-04-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Humanized sirpa-il15 knockin mice and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157667A1 (en) * 2009-06-29 2012-06-21 Qingfeng Chen Methods Of Producing Humanized Non-Human Mammals
US20110200982A1 (en) * 2009-10-06 2011-08-18 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
WO2012040207A3 (en) 2010-09-20 2012-08-09 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Proc Natl Acad Sci USA vol.108 no.32 pp.13218-13223(2011)
Trends Immunol. vol.32 no.7 pp.321-327(2011)

Also Published As

Publication number Publication date
CN104955326A (zh) 2015-09-30
KR102340059B1 (ko) 2021-12-17
NZ741951A (en) 2020-04-24
MX2019005251A (es) 2019-08-05
EP4606818A3 (en) 2025-10-22
CN113897398A (zh) 2022-01-07
CN108782459B (zh) 2021-11-05
KR20220164808A (ko) 2022-12-13
PT2892330T (pt) 2023-02-17
AU2013312359A8 (en) 2019-08-15
KR102473555B1 (ko) 2022-12-05
US20150208622A1 (en) 2015-07-30
MX385035B (es) 2025-03-14
EP4606818A2 (en) 2025-08-27
US20200093105A1 (en) 2020-03-26
WO2014039782A2 (en) 2014-03-13
IL265570B (en) 2021-05-31
AU2013312359B2 (en) 2019-05-23
KR20230153500A (ko) 2023-11-06
US12127537B2 (en) 2024-10-29
AU2019216625B2 (en) 2021-07-08
NZ704957A (en) 2018-05-25
JP2019110922A (ja) 2019-07-11
RU2642319C2 (ru) 2018-01-24
JP2022105531A (ja) 2022-07-14
KR102645622B1 (ko) 2024-03-11
EP4193834A1 (en) 2023-06-14
EP4193834B1 (en) 2025-05-14
JP6283031B2 (ja) 2018-02-21
AU2021240324A1 (en) 2021-10-28
ES3034290T3 (en) 2025-08-14
EP2892330A4 (en) 2016-07-27
CN113897398B (zh) 2025-07-08
IL307969A (en) 2023-12-01
JP2015529083A (ja) 2015-10-05
FI2892330T3 (fi) 2023-03-25
IL282472B2 (en) 2024-04-01
CN108782459A (zh) 2018-11-13
MX2015002983A (es) 2015-06-17
JP2020168024A (ja) 2020-10-15
MX364714B (es) 2019-05-06
IL282472B1 (en) 2023-12-01
JP6732998B2 (ja) 2020-07-29
US20180020647A1 (en) 2018-01-25
US20250072405A1 (en) 2025-03-06
EP2892330B1 (en) 2022-11-23
KR102241962B1 (ko) 2021-04-20
CN120718856A (zh) 2025-09-30
SG11201500504RA (en) 2015-02-27
WO2014039782A3 (en) 2015-07-23
KR20240045263A (ko) 2024-04-05
JP6517958B2 (ja) 2019-05-22
JP7605789B2 (ja) 2024-12-24
AU2013312359A1 (en) 2015-02-19
KR102594390B1 (ko) 2023-10-27
US9820476B2 (en) 2017-11-21
RU2017145913A3 (enExample) 2021-08-16
RU2015112607A (ru) 2016-10-27
CA2881468A1 (en) 2014-03-13
CA2881468C (en) 2023-03-21
HK1211176A1 (en) 2016-05-20
IL282472A (en) 2021-06-30
IL307969B1 (en) 2025-10-01
EP4193834C0 (en) 2025-05-14
US11026408B2 (en) 2021-06-08
SG10201701759VA (en) 2017-04-27
CN104955326B (zh) 2018-07-20
IL236877A0 (en) 2015-03-31
IL265570A (en) 2019-05-30
US20210368752A1 (en) 2021-12-02
KR20210044315A (ko) 2021-04-22
KR20150052274A (ko) 2015-05-13
KR20210156846A (ko) 2021-12-27
JP7066785B2 (ja) 2022-05-13
US20190082663A1 (en) 2019-03-21
EP2892330A2 (en) 2015-07-15
AU2013312359B8 (en) 2019-08-15
IN2015DN02032A (enExample) 2015-08-14
AU2019216625A1 (en) 2019-09-05
US10433527B2 (en) 2019-10-08
JP2018088925A (ja) 2018-06-14
AU2021240324B2 (en) 2024-02-22
RU2017145913A (ru) 2019-02-19
ES2938342T3 (es) 2023-04-10
NZ746089A (en) 2020-05-29
RU2768282C2 (ru) 2022-03-23
KR20210099664A (ko) 2021-08-12
DK2892330T3 (da) 2023-01-30

Similar Documents

Publication Publication Date Title
US12127537B2 (en) Genetically modified non-human animals and methods of use thereof
HK40095010B (en) Methods of using genetically modified mice
HK40095010A (en) Methods of using genetically modified mice
HK1211176B (en) Genetically modified mice and methods of use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5